GlassScriptPhysician profile
Khalid Hasan Sheikh
NPI 1639278427
$280,561.99
in general payments reported to CMS, 2019-2025
16 companies · $62.30 in 2025
The $62.30 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111K · 2020: $57K · 2021: $43K · 2022: $47K · 2023: $1,825 · 2024: $20K · 2025: $62.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Travel and Lodging: $4,297 · Food and Beverage: $1,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,950.50 |
| Travel and Lodging | $4,297.40 |
| Food and Beverage | $1,107.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $104,900.35 | 2020-2024 | Nexletol, Nexlizet |
| Amarin Pharma, INC. | $101,691.25 | 2019-2021 | |
| Amgen INC. | $72,469.62 | 2019-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $626.80 | 2020-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $176.09 | 2021-2025 | |
| Cvrx, INC. | $147.99 | 2022-2024 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $141.38 | 2020-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $85.20 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $70.94 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.56 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.32 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $42.63 | 2022-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $34.73 | 2019 | |
| Pfizer INC. | $33.40 | 2022 | |
| Trisalus Life Sciences, INC. | $30.83 | 2024 | Trinav Infusion System |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $18.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.